| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| Epoetin beta | Injection | 6666.66 IU/mL | Discontinued | Reduction in supply until supply is exhausted | Transport / Logistic issues / Storage capacity issues | 5/09/2025 |
| Epoetin beta | Injection | 10000 IU/mL | Discontinued | Reduction in supply until supply is exhausted | Transport / Logistic issues / Storage capacity issues | 5/09/2025 |
| Epoetin beta | Injection | 13333.33 IU/mL | Discontinued | Reduction in supply until supply is exhausted | Transport / Logistic issues / Storage capacity issues | 5/09/2025 |
| Epoetin beta | Injection | 16666.67 IU/mL | Discontinued | Reduction in supply until supply is exhausted | Transport / Logistic issues / Storage capacity issues | 5/09/2025 |
| Epoetin beta | Injection | 20000 IU/mL | Discontinued | Reduction in supply until supply is exhausted | Transport / Logistic issues / Storage capacity issues | 5/09/2025 |
| Epoetin beta | Injection | 16666.67 IU/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 5/09/2025 |
| prazosin hydrochloride | Tablet, uncoated | 2.19 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 5/09/2025 |
| bromocriptine mesilate | Tablet, uncoated | 2.87 mg | Current | Unavailable | Manufacturing | 5/09/2025 |
| topiramate | Tablet, film coated | 25 mg | Current | Limited Availability | Manufacturing | 5/09/2025 |
| ciprofloxacin hydrochloride | Tablet, film coated | 277.5 mg | Current | Unavailable | Manufacturing | 5/09/2025 |
| tetrabenazine | Tablet, uncoated | 25 mg | Anticipated | Available | Manufacturing | 5/09/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .125 mg | Current | Unavailable | Manufacturing | 5/09/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .25 mg | Current | Unavailable | Manufacturing | 5/09/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 43.38 mg | Anticipated | Available | Manufacturing | 5/09/2025 |
| galantamine hydrobromide | Capsule, modified release | 30.756 mg | Current | Unavailable | Manufacturing | 5/09/2025 |
| galantamine hydrobromide | Capsule, modified release | 30.756 mg | Current | Unavailable | Manufacturing | 5/09/2025 |
| montelukast sodium | Tablet, chewable | 5.2 mg | Current | Limited Availability | Manufacturing | 5/09/2025 |
| montelukast sodium | Tablet, chewable | 5.2 mg | Current | Unavailable | Unexpected increase in consumer demand | 5/09/2025 |
| ceftaroline fosamil | Injection, powder for | 600 mg | Current | Limited Availability | Manufacturing | 5/09/2025 |
| ropivacaine hydrochloride | Injection, solution | 100 mg | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 5/09/2025 |
| raloxifene hydrochloride | Tablet, film coated | 60 mg | Current | Unavailable | Manufacturing | 5/09/2025 |
| quetiapine fumarate | Tablet, modified release | 345.39 mg | Anticipated | Available | Manufacturing | 5/09/2025 |
| quetiapine fumarate | Tablet, modified release | 460.52 mg | Current | Limited Availability | Manufacturing | 5/09/2025 |
| quetiapine fumarate | Tablet, modified release | 345.39 mg | Anticipated | Available | Manufacturing | 5/09/2025 |
| Trastuzumab | Injection, solution | 600 mg | Anticipated | Available | Manufacturing | 5/09/2025 |
| linezolid | Tablet, film coated | 600 mg | Current | Unavailable | Manufacturing | 5/09/2025 |
| fenofibrate | Tablet, film coated | 145 mg | Anticipated | Available | Manufacturing | 5/09/2025 |
| oseltamivir phosphate | Capsule, hard | 98.524 mg | Current | Limited Availability | Manufacturing | 5/09/2025 |
| carboplatin | Injection, solution | 450 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 5/09/2025 |
| permethrin | Cream | 50 mg/g | Resolved | Available | Commercial Changes / Commercial viability | 5/09/2025 |
| abacavir sulfate~lamivudine | Tablet, film coated | 702 mg~300 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 5/09/2025 |
| calcitonin salmon | Injection, solution | 100 IU/mL | Resolved | Available | Commercial Changes / Commercial viability | 4/09/2025 |
| pentetic acid | Injection, powder for | 5 mg | Current | Unavailable | Manufacturing | 4/09/2025 |
| medronic acid | Injection, powder for | 10 mg | Current | Unavailable | Manufacturing | 4/09/2025 |
| lamotrigine | Tablet, chewable | 50 mg | Anticipated | Available | Manufacturing | 4/09/2025 |
| nystatin | Oral Liquid | 100000 IU/mL | Current | Unavailable | Commercial Changes / Commercial viability | 4/09/2025 |
| pioglitazone hydrochloride | Tablet | 16.63 mg | Resolved | Available | Manufacturing | 4/09/2025 |
| fampridine | Tablet, modified release | 10 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 4/09/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 21.69 mg | Current | Limited Availability | Manufacturing | 4/09/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 86.76 mg | Resolved | Available | Manufacturing | 4/09/2025 |
| ciprofloxacin hydrochloride | Tablet, film coated | 555 mg | Current | Unavailable | Manufacturing | 4/09/2025 |
| phenobarbital | Tablet, uncoated | 30 mg | Anticipated | Available | Manufacturing | 4/09/2025 |
| quetiapine fumarate | Tablet, modified release | 172.695 mg | Anticipated | Available | Manufacturing | 4/09/2025 |
| salmeterol xinafoate~fluticasone propionate | Inhalation, pressurised | 36.3 microgram/actuation~125 microgram/actuation | Anticipated | Available | Unexpected increase in consumer demand | 4/09/2025 |
| ropinirole hydrochloride | Tablet, film coated | .285 mg | Current | Limited Availability | Manufacturing | 4/09/2025 |
| oxaliplatin | Injection, concentrated | 100 mg | Current | Limited Availability | Manufacturing | 4/09/2025 |
| lacosamide | Tablet, film coated | 100 mg | Current | Limited Availability | Manufacturing | 4/09/2025 |
| GluureaLys(ahx)hbedCC | Injection, powder for | 25 microgram | Current | Unavailable | Manufacturing | 4/09/2025 |
| midazolam | Injection, solution | 1 mg/mL | Current | Limited Availability | Manufacturing | 4/09/2025 |
| estradiol hemihydrate | Drug delivery system, transdermal | 2.32 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 4/09/2025 |
| sodium valproate | Tablet, uncoated | 100 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 3/09/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .25 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 3/09/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .125 mg | Current | Unavailable | Manufacturing | 3/09/2025 |
| praziquantel | Tablet, film coated | 600 mg | Discontinued | Reduction in supply until supply is exhausted | Manufacturing | 3/09/2025 |
| ciprofloxacin hydrochloride | Tablet, film coated | 832.5 mg | Current | Unavailable | Manufacturing | 3/09/2025 |
| leuprorelin acetate~bicalutamide | Injection, modified release~Tablet, film coated | 7.5 mg~50 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 3/09/2025 |
| allopurinol | Tablet, uncoated | 100 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 3/09/2025 |
| tadalafil | Tablet, film coated | 5 mg | Current | Limited Availability | Manufacturing | 3/09/2025 |
| fluorouracil | Injection, solution | 50 mg/mL | Current | Unavailable | Manufacturing | 3/09/2025 |
| metaraminol tartrate | Injection, solution | 19 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 3/09/2025 |
| ramipril | Tablet, uncoated | 1.25 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 3/09/2025 |
| sitagliptin hydrochloride monohydrate~metformin hydrochloride | Tablet, film coated | 56.69 mg~1000 mg | Current | Unavailable | Manufacturing | 3/09/2025 |
| framycetin sulfate | Eye and Ear Drops | 5 mg/mL | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 3/09/2025 |
| imipramine hydrochloride | Tablet, sugar coated | 25 mg | Current | Unavailable | Manufacturing | 3/09/2025 |
| pantoprazole sodium sesquihydrate | Tablet, enteric coated | 45.4 mg | Current | Limited Availability | Unexpected increase in consumer demand | 2/09/2025 |
| midazolam | Injection, solution | 5 mg | Current | Limited Availability | Manufacturing | 2/09/2025 |
| doxorubicin hydrochloride | Injection, concentrated | 2 mg/mL | Resolved | Available | Manufacturing | 2/09/2025 |
| clopidogrel hydrogen sulfate | Tablet, film coated | 97.875 mg | Current | Limited Availability | Unexpected increase in consumer demand | 2/09/2025 |
| rosuvastatin calcium | Tablet, film coated | 41.68 mg | Current | Limited Availability | Manufacturing | 2/09/2025 |
| pregabalin | Capsule, hard | 75 mg | Current | Limited Availability | Manufacturing | 2/09/2025 |
| levetiracetam | Solution | 100 mg/mL | Anticipated | Available | Manufacturing | 2/09/2025 |
| clonidine hydrochloride | Tablet | 100 microgram | Current | Limited Availability | Unexpected increase in consumer demand | 2/09/2025 |
| solifenacin succinate | Tablet | 10 mg | Resolved | Available | Manufacturing | 2/09/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 86.76 mg | Current | Unavailable | Manufacturing | 2/09/2025 |
| moxonidine | Tablet, film coated | 400 microgram | Anticipated | Available | Commercial Changes / Commercial viability | 2/09/2025 |
| moxonidine | Tablet, film coated | 200 microgram | Anticipated | Available | Commercial Changes / Commercial viability | 2/09/2025 |
| dabigatran etexilate mesilate | Capsule, hard | 172.95 mg | Current | Unavailable | Manufacturing | 2/09/2025 |
| teriflunomide | Tablet, film coated | 14 mg | Current | Limited Availability | Manufacturing | 2/09/2025 |
| amiodarone hydrochloride | Tablet, uncoated | 100 mg | Current | Unavailable | Manufacturing | 2/09/2025 |
| spironolactone | Tablet, uncoated | 25 mg | Current | Unavailable | Manufacturing | 2/09/2025 |
| spironolactone | Tablet, uncoated | 100 mg | Current | Limited Availability | Manufacturing | 2/09/2025 |
| flecainide acetate | Tablet | 50 mg | Current | Unavailable | Manufacturing | 2/09/2025 |
| sacubitril~valsartan | Tablet, film coated | 48.6 mg~51.4 mg | Current | Unavailable | Manufacturing | 2/09/2025 |
| sacubitril~valsartan | Tablet, film coated | 97.2 mg~102.8 mg | Current | Unavailable | Manufacturing | 2/09/2025 |
| sugammadex sodium | Injection, solution | 217.6 mg | Current | Limited Availability | Manufacturing | 2/09/2025 |
| tetrabenazine | Tablet, uncoated | 25 mg | Current | Limited Availability | Manufacturing | 2/09/2025 |
| rifampicin | Capsule, hard | 150 mg | Current | Limited Availability | Manufacturing | 2/09/2025 |
| rocuronium bromide | Injection, solution | 50 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 1/09/2025 |
| dopamine hydrochloride | Injection, concentrated | 40 mg/mL | Resolved | Available | Unexpected increase in consumer demand | 1/09/2025 |
| propranolol hydrochloride | Tablet, film coated | 40 mg | Current | Unavailable | Manufacturing | 1/09/2025 |
| meloxicam | Capsule, hard | 7.5 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 1/09/2025 |
| meloxicam | Capsule, hard | 15 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 1/09/2025 |
| atorvastatin calcium trihydrate~ezetimibe | Tablet, multilayer | 10.9 mg~10 mg | Current | Limited Availability | Manufacturing | 1/09/2025 |
| prochlorperazine maleate | Tablet, uncoated | 5 mg | Current | Unavailable | Commercial Changes / Commercial viability | 1/09/2025 |
| celecoxib | Capsule, hard | 100 mg | Resolved | Available | Manufacturing | 1/09/2025 |
| atovaquone~proguanil hydrochloride | Tablet, film coated | 250 mg~100 mg | Current | Limited Availability | Manufacturing | 1/09/2025 |
| stannous chloride dihydrate | Injection, powder for | 19.2 microgram/mL | Current | Limited Availability | Manufacturing | 1/09/2025 |
| citalopram hydrobromide | Tablet, film coated | 49.96 mg | Current | Unavailable | Manufacturing | 1/09/2025 |
| galantamine~galantamine hydrobromide | Capsule, modified release | 16 mg~20.51 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 1/09/2025 |
2025年9月8日